Learn More
BACKGROUND Angiomyolipomas are slow-growing tumours associated with constitutive activation of mammalian target of rapamycin (mTOR), and are common in patients with tuberous sclerosis complex and(More)
Increased activation of the PI3K/Akt/mTOR pathway is a common factor in putative mechanisms of trastuzumab resistance, resulting in dysregulation of cell migration, growth, proliferation, and(More)
4009 Background: In the RADIANT-3 trial, everolimus, an oral inhibitor of mTOR, significantly prolonged progression-free survival (PFS) in pts with advanced pNET (ESMO 2010, Abstract #LBA9). Updated(More)